Sign inCreate account

Report workspace

Add to folder
NCT04642950COMPLETEDanonymous

A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19)

Sponsor

Source record

Nobelpharma

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Sargramostim, Placebo

Indication / condition

AI-normalized

COVID-19

Intervention

Source record

Sargramostim, Placebo

Related intelligence directories

Indication directory: COVID-19Modality directory: small moleculeTarget directory: Sargramostim

Source & freshness

Source record

NCT ID

NCT04642950

Original source

ClinicalTrials.gov

Source last updated

Jul 19, 2024

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04642950

Title

A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19)

Sponsor

Nobelpharma

Status

COMPLETED

Phase

PHASE2

Condition raw

COVID-19

Condition normalized

COVID-19

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Sargramostim, Placebo

Target normalized

Sargramostim, Placebo

Interventions

Sargramostim, Placebo

Public preview

Source record

This is a randomized, placebo-controlled, double-blind, group comparison, multicenter study to evaluate the efficacy and safety of inhalation administration of sargramostim for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment in COVID-19 patients.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase II/III Study of Sargramostim in Patients With Coronavirus Disease-2019 (COVID-19)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT04642950

Status

COMPLETED

Phase

PHASE2

Sponsor

Nobelpharma

Executive brief

Investment-Ready Snapshot

This is a randomized, placebo-controlled, double-blind, group comparison, multicenter study to evaluate the efficacy and safety of inhalation administration of sargramostim for 5 days, in principle (up to 10 days) as Add-on treatment to the standard treatment in COVID-19 patients.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJul 19, 2024
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04642950

Indication

COVID-19

Modality

small molecule

Target

Sargramostim, Placebo

Intervention

Sargramostim, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.